Wednesday, February 21, 2018 7:23:17 AM
I'm not sure what would constitute a disappointment. They've given very little near term guidance and the market cap is only $1.5mm. I'd say expectations have been sucked out of this stock, which is a good thing. Anshu had done a terrible job managing expectations for the first couple of quarters of his tenure. He keeps blaming outside factors, but he needed to own up to his mistakes (like letting the Monaker lawsuit drag on much too long).
That said, the stock is setup up much better now assuming he's being truthful on conversions and incremental dilution. He needs to figure out a way to prime the pump with non-dilutive or minimally dilutive financing so he can get the cash flowing to fulfill orders (assuming his contracts are still valid).
I think $0.03-$0.05 is realistic if we get a decent report and achievable guidance. From there, he'll just have to deliver on existing contracts for the stock to work to $0.10-$0.20 assuming he can do this in a shareholder friendly manner.
There's a lot of assumptions and not a lot of certainty at this point, but that's partly why the market cap is so low.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM